$60,000 of ALNYLAM PHARMACEUTICALS INC. lobbying was just disclosed, from Q1 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act; Issues related to H.R. 1672 - Maintaining Investments in New Innovation Act; Issues related to Medicare and Medicaid drug pricing."
You can find more data on corporate lobbying on Quiver Quantitative.
ALNY Insider Trading Activity
ALNY insiders have traded $ALNY stock on the open market 273 times in the past 6 months. Of those trades, 0 have been purchases and 273 have been sales.
Here’s a breakdown of recent trading of $ALNY stock by insiders over the last 6 months:
- YVONNE GREENSTREET (Chief Executive Officer) has made 0 purchases and 60 sales selling 51,917 shares for an estimated $20,420,981.
- KEVIN JOSEPH FITZGERALD (CSO & EVP, Head of Research) has made 0 purchases and 66 sales selling 24,469 shares for an estimated $9,634,419.
- PUSHKAL GARG (EVP Chief R&D) has made 0 purchases and 53 sales selling 16,584 shares for an estimated $5,431,156.
- JEFFREY V. POULTON (EVP, Chief Financial Officer) has made 0 purchases and 40 sales selling 9,696 shares for an estimated $3,224,118.
- TOLGA TANGULER (EVP, Chief Commercial Officer) has made 0 purchases and 40 sales selling 7,376 shares for an estimated $2,424,943.
- MELISSA MCLAUGHLIN (Chief Human Resources Officer) has made 0 purchases and 14 sales selling 3,910 shares for an estimated $1,274,342.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ALNY Hedge Fund Activity
We have seen 410 institutional investors add shares of ALNY stock to their portfolio, and 416 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 2,181,890 shares (-77.0%) from their portfolio in Q4 2025, for an estimated $867,628,558
- REGENERON PHARMACEUTICALS, INC. removed 1,392,303 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $553,649,287
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,022,637 shares (-47.0%) from their portfolio in Q4 2025, for an estimated $406,651,603
- FMR LLC removed 865,476 shares (-5.2%) from their portfolio in Q4 2025, for an estimated $344,156,531
- BANK OF AMERICA CORP /DE/ removed 813,314 shares (-54.3%) from their portfolio in Q4 2025, for an estimated $323,414,312
- INVESCO LTD. added 683,998 shares (+46.2%) to their portfolio in Q4 2025, for an estimated $271,991,804
- JANE STREET GROUP, LLC removed 647,462 shares (-67.5%) from their portfolio in Q4 2025, for an estimated $257,463,264
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ALNY Analyst Ratings
Wall Street analysts have issued reports on $ALNY in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- B of A Securities issued a "Buy" rating on 01/30/2026
- Barclays issued a "Overweight" rating on 01/28/2026
- Needham issued a "Buy" rating on 01/12/2026
- Truist Securities issued a "Buy" rating on 01/08/2026
- Stifel issued a "Buy" rating on 12/11/2025
- Piper Sandler issued a "Overweight" rating on 10/31/2025
- Jefferies issued a "Buy" rating on 10/30/2025
To track analyst ratings and price targets for ALNY, check out Quiver Quantitative's $ALNY forecast page.
ALNY Price Targets
Multiple analysts have issued price targets for $ALNY recently. We have seen 17 analysts offer price targets for $ALNY in the last 6 months, with a median target of $465.0.
Here are some recent targets:
- Danielle Brill from Truist Securities set a target price of $505.0 on 04/13/2026
- Patrick R. Trucchio from HC Wainwright & Co. set a target price of $510.0 on 03/25/2026
- Keay Nakae from Chardan Capital set a target price of $425.0 on 03/25/2026
- Faisal Khurshid from Jefferies set a target price of $330.0 on 03/16/2026
- Whitney Ijem from Canaccord Genuity set a target price of $429.0 on 02/17/2026
- Ilya Zubkov from Freedom Capital Markets set a target price of $410.0 on 02/17/2026
- Joseph Stringer from Needham set a target price of $510.0 on 02/12/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
